A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors

Barun Okram, Advait Nagle, Francisco J. Adrián, Christian Lee, Pingda Ren, Xia Wang, Taebo Sim, Yongping Xie, Xing Wang, Gang Xia, Glen Spraggon, Markus Warmuth, Yi Liu, Nathanael S. Gray

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Kinase inhibitors that bind to the ATP cleft can be broadly classified into two groups: those that bind exclusively to the ATP site with the kinase assuming a conformation otherwise conducive to phosphotransfer (type I), and those that exploit a hydrophobic site immediately adjacent to the ATP pocket made accessible by a conformational rearrangement of the activation loop (type II). To date, all type II inhibitors were discovered by using structure-activity-guided optimization strategies. Here, we describe a general pharmacophore model of type II inhibition that enables a rational "hybrid-design" approach whereby a 3-trifluoromethylbenzamide functionality is appended to four distinct type I scaffolds in order to convert them into their corresponding type II counterparts. We demonstrate that the designed compounds function as type II inhibitors by using biochemical and cellular kinase assays and by cocrystallography with Abl.

Original languageEnglish
Pages (from-to)779-786
Number of pages8
JournalChemistry and Biology
Volume13
Issue number7
DOIs
Publication statusPublished - 2006 Jul 1
Externally publishedYes

Fingerprint

Conformations
Phosphotransferases
Adenosine Triphosphate
Scaffolds
Assays
Chemical activation

Keywords

  • CHEMBIO
  • SIGNALING

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Okram, B., Nagle, A., Adrián, F. J., Lee, C., Ren, P., Wang, X., ... Gray, N. S. (2006). A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors. Chemistry and Biology, 13(7), 779-786. https://doi.org/10.1016/j.chembiol.2006.05.015

A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors. / Okram, Barun; Nagle, Advait; Adrián, Francisco J.; Lee, Christian; Ren, Pingda; Wang, Xia; Sim, Taebo; Xie, Yongping; Wang, Xing; Xia, Gang; Spraggon, Glen; Warmuth, Markus; Liu, Yi; Gray, Nathanael S.

In: Chemistry and Biology, Vol. 13, No. 7, 01.07.2006, p. 779-786.

Research output: Contribution to journalArticle

Okram, B, Nagle, A, Adrián, FJ, Lee, C, Ren, P, Wang, X, Sim, T, Xie, Y, Wang, X, Xia, G, Spraggon, G, Warmuth, M, Liu, Y & Gray, NS 2006, 'A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors', Chemistry and Biology, vol. 13, no. 7, pp. 779-786. https://doi.org/10.1016/j.chembiol.2006.05.015
Okram, Barun ; Nagle, Advait ; Adrián, Francisco J. ; Lee, Christian ; Ren, Pingda ; Wang, Xia ; Sim, Taebo ; Xie, Yongping ; Wang, Xing ; Xia, Gang ; Spraggon, Glen ; Warmuth, Markus ; Liu, Yi ; Gray, Nathanael S. / A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors. In: Chemistry and Biology. 2006 ; Vol. 13, No. 7. pp. 779-786.
@article{2f2bc4d904a94c668e9558f23a139aab,
title = "A General Strategy for Creating {"}Inactive-Conformation{"} Abl Inhibitors",
abstract = "Kinase inhibitors that bind to the ATP cleft can be broadly classified into two groups: those that bind exclusively to the ATP site with the kinase assuming a conformation otherwise conducive to phosphotransfer (type I), and those that exploit a hydrophobic site immediately adjacent to the ATP pocket made accessible by a conformational rearrangement of the activation loop (type II). To date, all type II inhibitors were discovered by using structure-activity-guided optimization strategies. Here, we describe a general pharmacophore model of type II inhibition that enables a rational {"}hybrid-design{"} approach whereby a 3-trifluoromethylbenzamide functionality is appended to four distinct type I scaffolds in order to convert them into their corresponding type II counterparts. We demonstrate that the designed compounds function as type II inhibitors by using biochemical and cellular kinase assays and by cocrystallography with Abl.",
keywords = "CHEMBIO, SIGNALING",
author = "Barun Okram and Advait Nagle and Adri{\'a}n, {Francisco J.} and Christian Lee and Pingda Ren and Xia Wang and Taebo Sim and Yongping Xie and Xing Wang and Gang Xia and Glen Spraggon and Markus Warmuth and Yi Liu and Gray, {Nathanael S.}",
year = "2006",
month = "7",
day = "1",
doi = "10.1016/j.chembiol.2006.05.015",
language = "English",
volume = "13",
pages = "779--786",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors

AU - Okram, Barun

AU - Nagle, Advait

AU - Adrián, Francisco J.

AU - Lee, Christian

AU - Ren, Pingda

AU - Wang, Xia

AU - Sim, Taebo

AU - Xie, Yongping

AU - Wang, Xing

AU - Xia, Gang

AU - Spraggon, Glen

AU - Warmuth, Markus

AU - Liu, Yi

AU - Gray, Nathanael S.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Kinase inhibitors that bind to the ATP cleft can be broadly classified into two groups: those that bind exclusively to the ATP site with the kinase assuming a conformation otherwise conducive to phosphotransfer (type I), and those that exploit a hydrophobic site immediately adjacent to the ATP pocket made accessible by a conformational rearrangement of the activation loop (type II). To date, all type II inhibitors were discovered by using structure-activity-guided optimization strategies. Here, we describe a general pharmacophore model of type II inhibition that enables a rational "hybrid-design" approach whereby a 3-trifluoromethylbenzamide functionality is appended to four distinct type I scaffolds in order to convert them into their corresponding type II counterparts. We demonstrate that the designed compounds function as type II inhibitors by using biochemical and cellular kinase assays and by cocrystallography with Abl.

AB - Kinase inhibitors that bind to the ATP cleft can be broadly classified into two groups: those that bind exclusively to the ATP site with the kinase assuming a conformation otherwise conducive to phosphotransfer (type I), and those that exploit a hydrophobic site immediately adjacent to the ATP pocket made accessible by a conformational rearrangement of the activation loop (type II). To date, all type II inhibitors were discovered by using structure-activity-guided optimization strategies. Here, we describe a general pharmacophore model of type II inhibition that enables a rational "hybrid-design" approach whereby a 3-trifluoromethylbenzamide functionality is appended to four distinct type I scaffolds in order to convert them into their corresponding type II counterparts. We demonstrate that the designed compounds function as type II inhibitors by using biochemical and cellular kinase assays and by cocrystallography with Abl.

KW - CHEMBIO

KW - SIGNALING

UR - http://www.scopus.com/inward/record.url?scp=33746258750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746258750&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2006.05.015

DO - 10.1016/j.chembiol.2006.05.015

M3 - Article

C2 - 16873026

AN - SCOPUS:33746258750

VL - 13

SP - 779

EP - 786

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 7

ER -